Gene augmentation for adRP mutations in RHO

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Mutations in the rhodopsin (RHO) gene cause autosomal dominant retinitis pigmentosa (adRP), leading to photoreceptor cell death and vision loss.
• adRP pathogenesis involves both interference with normal rhodopsin function and intrinsic toxicity of mutant rhodopsin proteins.
• Preserving central vision by promoting rod photoreceptor survival, particularly in the macula, is a key goal for adRP gene therapy.

Purpose of the Study:

• To investigate therapeutic strategies for autosomal dominant retinitis pigmentosa (adRP) by targeting rhodopsin (RHO) gene mutations.
• To evaluate the efficacy of RHO augmentation and RHO suppression in preserving rod photoreceptor cells in adRP models.
• To explore the potential of gene therapy for maintaining central vision in patients with adRP.

Main Methods:

• Utilized adeno-associated virus (AAV) for gene delivery to the retina.
• Developed and tested strategies for RHO gene augmentation to increase wild-type protein levels.
• Implemented and assessed methods for suppressing rhodopsin expression, noting their non-specific nature.
• Conducted experiments using autosomal dominant retinitis pigmentosa (adRP) mouse models.

Main Results:

• Both RHO augmentation and a combined RHO supplementation plus suppression strategy were effective.
• These strategies demonstrated the preservation of rod photoreceptor cell survival in adRP mouse models.
• The study highlights the potential of gene-based interventions for adRP.

Conclusions:

• Gene therapy approaches targeting rhodopsin (RHO) gene mutations show significant promise for treating autosomal dominant retinitis pigmentosa (adRP).
• RHO augmentation and combined suppression strategies can preserve rod photoreceptor cells, potentially safeguarding vision in adRP patients.
• Further research into allele-specific suppression could enhance therapeutic specificity and efficacy.